Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis
Authors:
- 22 November 2016
- journal article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 176 (3) , 752-758
Abstract
The pro-inflammatory cytokine interleukin (IL)-17A plays a pivotal role in psoriasis pathogenesis. Secukinumab, a fully human monoclonal antibody (mAb) that selectively targets IL-17A, has been demonstrated to be highly efficacious for treatment of moderate to severe psoriasis, starting at early time points, with a sustained effect and a favourable safety profile. mAb therapies may be associated with production of antidrug antibodies (ADA) that can affect drug pharmacokinetics, diminish response, or cause hypersensitivity reactions. To investigate the immunogenicity of secukinumab across six phase 3 clinical trials of plaque psoriasis subjects treated with secukinumab for up to 52 weeks and an additional follow-up time point at Week 60. Immunogenicity in plaque psoriasis subjects exposed to secukinumab was evaluated at Baseline and at Weeks 12, 24, 52 and 60. Treatment-emergent ADA (TE-ADA) were defined as a positive ADA signal detected in post-treatment samples from subjects with a negative Baseline signal. Confirmed positive samples were further analysed for drug-neutralising potential. Among 2,842 subjects receiving secukinumab and evaluated for ADA, 11 (0.4%) developed TE-ADA. Associations between TE-ADA and secukinumab dose, frequency, or mode of administration were not observed. Neutralising antibodies were detected in three of nine evaluable subjects with TE-ADA. Secukinumab immunogenicity was low as demonstrated by evidence that TE-ADA were detected in 11 of 2,842 (0.4%) moderate to severe plaque psoriasis subjects treated with secukinumab. All but one of the subjects with TE-ADA were biologics naïve. Neither TE-ADA nor neutralising antibodies were associated with loss of secukinumab efficacy or issues of clinical concern.Keywords
Funding Information
- Novartis Pharma
This publication has 29 references indexed in Scilit:
- Global Epidemiology of Psoriasis: A Systematic Review of Incidence and PrevalenceJournal of Investigative Dermatology, 2013
- The Emerging Role of IL-17 in the Pathogenesis of Psoriasis: Preclinical and Clinical FindingsJournal of Investigative Dermatology, 2013
- Epidemiology and comorbidities of psoriasis patients in a national database in TaiwanJournal of Dermatological Science, 2011
- Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in PsoriasisThe Journal of Immunology, 2011
- Overrepresentation of IL-17A and IL-22 Producing CD8 T Cells in Lesional Skin Suggests Their Involvement in the Pathogenesis of PsoriasisPLOS ONE, 2010
- IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokinesJournal of Leukocyte Biology, 2009
- Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skinBritish Journal of Dermatology, 2009
- Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T CellsJournal of Investigative Dermatology, 2008
- Pathogenesis and clinical features of psoriasisThe Lancet, 2007
- Quality of Life in Patients with Psoriasis: A Systematic Literature ReviewJournal of Investigative Dermatology Symposium Proceedings, 2004